Core Insights - Kessler Topaz Meltzer & Check, LLP is investigating potential violations of federal securities laws on behalf of investors of Commvault Systems, Inc. [1] Financial Performance - Commvault reported a 40% growth in SaaS ARR to $364 million for the third quarter of fiscal 2026, which ended on December 31, 2025 [2] - The growth rate of 40% represents a significant deceleration from the 56% growth reported for the second quarter of fiscal 2026 [2] Stock Market Reaction - Following the financial results announcement, Commvault's stock price fell by $40.23 per share, approximately 31.1%, from a closing price of $129.36 on January 26, 2026, to $89.13 on January 27, 2026 [3]

Core Viewpoint - Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against uniQure N.V. on behalf of investors who purchased shares during a specified class period, alleging that the company made materially false and misleading statements regarding its drug AMT-130 and its regulatory approval process [1][11]. Company Overview - uniQure N.V. is a biotechnology company focused on developing gene therapies for rare diseases, including Huntington's disease (HD) [3]. - The company's leading drug candidate, AMT-130, aims to slow the progression of HD, a fatal genetic disorder with no existing cure [4]. Clinical Trials and FDA Interaction - uniQure completed patient enrollment for two ongoing Phase I/II clinical trials for AMT-130, known as the Pivotal Study, in March 2022 [4]. - The FDA had previously agreed that the Pivotal Study would not include a placebo comparator, allowing results to be compared to an external historical dataset, ENROLL-HD, for potential BLA submission [5]. Investor Communication and Stock Performance - On September 24, 2025, uniQure announced topline results from the Pivotal Study, leading to a significant increase in share price from $13.66 to $47.50, a nearly 250% rise [8]. - By October 29, 2025, shares were trading above $70.00, prompting the company to offer over 5.7 million shares to capitalize on the increased valuation, generating approximately $345 million [9]. Disclosure of Regulatory Challenges - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that the data from the Pivotal Study would be adequate for BLA submission, leading to a sharp decline in share price by over 49% [10]. Allegations in the Lawsuit - The lawsuit alleges that uniQure misrepresented the approval status of the Pivotal Study design and downplayed the likelihood of delays in the BLA timeline, resulting in misleading statements about the company's business and prospects [11].

Core Viewpoint - KDDI Corporation is under investigation for potential violations of federal securities laws, which may impact investors who have incurred losses [1] Investigation Details - The investigation is initiated by the Law Offices of Frank R. Cruz on behalf of investors [1] - KDDI announced on February 6, 2026, that it decided to postpone certain unspecified actions, raising concerns among investors [1]

Group 1 - Richtech Robotics Inc. is facing a class action lawsuit due to allegations of misleading investors about its relationship with Microsoft [1][1] - The lawsuit claims that Richtech Robotics falsely stated it had a commercial partnership with Microsoft, which was denied by Microsoft in a published article [1][1] - Following the news of the denied partnership, Richtech Robotics Class B stock price dropped over 29% within two trading days [1][1] Group 2 - The class action lawsuit allows investors who suffered substantial losses during the specified Class Period to seek appointment as lead plaintiff [1][1] - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized as a leading firm in securities fraud litigation, having recovered over $916 million for investors in 2025 alone [1][1] - The firm has a history of significant recoveries, totaling $8.4 billion for investors over the past five years [1][1]

Core Viewpoint - BlackRock TCP Capital Corp. is facing a securities fraud class action lawsuit due to alleged misrepresentations regarding the valuation of its investments and the quality of its portfolio [1] Group 1: Lawsuit Details - The lawsuit claims that from November 6, 2024, to January 23, 2026, the company failed to disclose that its investments were not being valued appropriately [1] - Allegations include ineffective portfolio restructuring efforts that did not resolve challenged credits or improve portfolio quality [1] - The complaint states that the company's unrealized losses were understated, leading to an overstated Net Asset Value (NAV) [1] Group 2: Investor Participation - Investors who suffered losses in BlackRock TCP Capital Corp. are encouraged to contact the Law Offices of Howard G. Smith to participate in the class action lawsuit [1] - The deadline for potential lead plaintiffs to join the lawsuit is April 6, 2026 [1] - Interested investors can retain counsel or remain absent members of the class action without taking immediate action [1]

Core Viewpoint - Hagens Berman is notifying investors about a pending securities class action against F5, Inc. due to allegations of misleading statements regarding the security of its BIG-IP products, which resulted in significant financial losses for investors [1][2]. Group 1: Allegations and Impact - The lawsuit claims that F5 executives misled the market about the security of its core products, particularly after a sophisticated nation-state threat actor allegedly accessed F5's systems and exfiltrated sensitive source code [2][9]. - Following the revelation of the security breach in October 2025, F5's market value dropped by over $2 billion due to a significant decline in stock price [2][9]. - The breach was disclosed on October 15, 2025, revealing that the threat actor had maintained long-term access to F5's systems, which included critical product development environments [9]. Group 2: Financial Performance and Guidance - F5's disappointing fourth-quarter fiscal 2025 results, released on October 27, 2025, indicated a significant reduction in expected sales and renewals, elongated sales cycles, and increased expenses due to ongoing remediation efforts [9]. - The company announced that the BIG-IP product, which was the subject of the breach, is its highest revenue-generating product, and the stock price fell by $22.83, or 7%, the following day [9]. - The revenue guidance for fiscal 2026 was significantly below market expectations, attributed largely to the impact of the security breach [9]. Group 3: Legal Proceedings and Next Steps - The lead plaintiff deadline for the class action lawsuit is set for February 17, 2026, and the class period is defined from October 28, 2024, to October 27, 2025 [5][7]. - Hagens Berman is actively investigating the claims and advising investors who suffered losses during the class period [4][7].

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged securities fraud affecting investors between August 3, 2023, and December 26, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Ultragenyx made misleading statements regarding the efficacy of setrusumab, particularly that while it increases bone density, it does not correlate with a decrease in annualized fracture rates [1] - On December 29, 2025, Ultragenyx announced that its Phase III Orbit and Cosmic Studies did not achieve statistical significance in reducing annualized clinical fracture rates compared to placebo or bisphosphonates [1] - Following the announcement, Ultragenyx's stock price plummeted from $34.19 per share on December 26, 2025, to $19.72 per share on December 29, 2025, marking a decline of approximately 42.32% in just one day [1] Group 2: Investor Information - Investors who suffered losses during the relevant time frame have until April 6, 2026, to request to be appointed as lead plaintiff in the lawsuit [1] - Class members may be entitled to compensation without any out-of-pocket costs or fees [1] - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [1]

Lost Money on Richtech Robotics Inc.(RR)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky [Accessibility Statement] Skip NavigationNEW YORK, Feb. 11, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Richtech Robotics Inc. ("Richtech" or the "Company") (NASDAQ: RR) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Richtech investors who were adversely affected by alleged securities fraud between January 27, 2026 and Janu ...

March 9, 2026 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ARDT [Accessibility Statement] Skip NavigationNEW YORK, Feb. 11, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Ardent Health, Inc. ("Ardent Health, Inc." or the "Company") (NYSE: ARDT) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Ardent Health, Inc. investors who were adversely affected by alleged securities fraud between July 18, 2024 and November ...

Lost Money on Oracle Corporation(ORCL)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky [Accessibility Statement] Skip NavigationNEW YORK, Feb. 11, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Oracle Corporation ("Oracle" or the "Company") (NYSE: ORCL) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Oracle investors who were adversely affected by alleged securities fraud between June 12, 2025 and December 16, 2025 ...